Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

13.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 13.04
Bid (Size) 10.65 (1)
Ask (Size) 13.70 (1)
Prev. Close 13.04
Today's Range 13.04 - 13.04
52wk Range 9.290 - 17.82
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus Reports Third Quarter 2024 Results
From Evolus
Via Business Wire
Evolus to Participate in Stifel 2024 Healthcare Conference
From Evolus
Via Business Wire

Performance

YTD
+30.53%
+30.53%
1 Month
-18.70%
-18.70%
3 Month
-15.76%
-15.76%
6 Month
+4.74%
+4.74%
1 Year
+38.72%
+38.72%

More News

Read More
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
From Evolus
Via Business Wire
A Closer Look at 5 Analyst Recommendations For Evolus
Via Benzinga
Analyst Scoreboard: 4 Ratings For Evolus
Via Benzinga
Evolus: Chiseling Away At The Aesthetic Market
Via Talk Markets
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
From Evolus, Inc.
Via Business Wire
Evolus to Report Third Quarter Financial Results on November 6, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Via Investor's Business Daily
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
From Evolus
Via Business Wire
Evolus to Hold Investor Day on September 12, 2024
From Evolus
Via Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
From Evolus, Inc.
Via Business Wire
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Evolus
Via Business Wire
Evolus to Report Second Quarter Financial Results on July 31, 2024
From Evolus
Via Business Wire
Evolus Announces Appointment of Albert G. White III to Board of Directors
From Evolus
Via Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
From Evolus
Via Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
From Evolus
Via Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
From Evolus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.